APA (7th ed.) Citation

RM, R., CL, C., RE, B., S, K., J, R., R, A., . . . S, G. (2024). In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future oncology (London, England), 20(3), 131. https://doi.org/10.2217/fon-2023-0272

Chicago Style (17th ed.) Citation

RM, Rifkin, et al. "In-class Transition from Bortezomib-based Therapy to IRd Is an Effective Approach in Newly Diagnosed Multiple Myeloma." Future Oncology (London, England) 20, no. 3 (2024): 131. https://doi.org/10.2217/fon-2023-0272.

MLA (9th ed.) Citation

RM, Rifkin, et al. "In-class Transition from Bortezomib-based Therapy to IRd Is an Effective Approach in Newly Diagnosed Multiple Myeloma." Future Oncology (London, England), vol. 20, no. 3, 2024, p. 131, https://doi.org/10.2217/fon-2023-0272.